UK’s NICE turns down Glaxo Tyverb offer

LONDON (Reuters) - Britain’s healthcare cost effectiveness watchdog NICE has rebuffed GlaxoSmithKline’s latest bid to get its drug Tyverb - for women with advanced breast cancer - into the state health system, the company said on Tuesday.

Glaxo said as part of the ongoing appeal it had offered to run a 12-week trial in women with advanced breast cancer to show the drug is good value for money.

In June, Glaxo received formal European marketing authorization for its new breast cancer pill Tyverb.

Tyverb — which is already sold as Tykerb in the United States — is designed to be given in combination with Roche’s Xeloda for treating breast cancer patients whose tumors overexpress the HER2 protein.

Glaxo is seeking to convince NICE, which determines whether drugs are cost-effective, to overturn an earlier draft recommendation that the medicine should not be included in the state health system.

NICE is expected to make a final decision at a meeting on November 19.

(Reporting by Ben Deighton, Editing by David Cowell)


Related Posts:

LONDON (Reuters) - Roche Holding AG’s lung cancer drug Tarceva has won final approval for use by Britain’s state health service after the Swiss drugmaker agreed to discount the price of the medicine. The National Institute for Health and Clinical Excellence (NICE) now recommends Tarceva as an alternative to Sanofi-Aventis SA’s Taxotere for people who have

Full Post: Roche wins final UK okay for discounted Tarceva

* Avastin meets goal in breast cancer clinical trial * Study shows Avastin can be added to common chemotherapies * Roche stock up 4.1 percent ZURICH (Reuters) - Roche Holding AG, the world’s largest maker of cancer drugs, said on Monday that Avastin met its primary endpoint in a Phase III breast cancer trial. Roche said Avastin, which it

Full Post: Study boosts Roche’s Avastin in breast cancer

LONDON (Reuters) - Greek researchers have identified the chemotherapy combinations that appear to help women with advanced breast cancer live longest, they reported Tuesday. Women who took a combination of a taxane-based therapy such as Taxol or paclitaxel, or Sanofi Aventis’s Taxotere, known generically as docetaxel, with other drugs lived a year longer than women who

Full Post: Certain chemotherapy combinations work best

By Julie Steenhuysen CHICAGO (Reuters) - A screening schedule that alternates between a breast MRI and a mammogram every six months may do a better job of spotting early cancers in high-risk women than an annual exam, U.S. researchers said on Saturday. Women who are at high risk for breast cancer currently get a yearly mammogram and

Full Post: Rotating breast cancer tests helps high-risk women

CHICAGO (Reuters) - A study of nearly 40,000 women has found no overall link between caffeine and breast cancer, though some women who have benign breast lumps might be at a higher risk, researcher said on Monday. A few earlier studies had suggested caffeine could play a role in breast cancer among those who consume what

Full Post: No overall caffeine-breast cancer link: study

Site Navigation

Most Read